<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02003339</url>
  </required_header>
  <id_info>
    <org_study_id>2012-JE-CHC-Pron</org_study_id>
    <secondary_id>2012-A00972-41</secondary_id>
    <nct_id>NCT02003339</nct_id>
  </id_info>
  <brief_title>Interest of Functional MRI (Magnetic Resonance Imagery) (in Patients Suffering From Hepatocellular Carcinoma and Treated With Yttrium</brief_title>
  <acronym>ICY</acronym>
  <official_title>Pilot Prospective Study on Interest of Functional MRI in Early Assessment of Radioembolization Efficiency in Patients Suffering From Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Center Eugene Marquis</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Center Eugene Marquis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients who are suffering from hepatocellular carcinoma and are treated with
      radioembolization, the purpose of this study is to analyse parameters of functional MRIs that
      are modified early and to detect parameters that vary significantly after treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">November 8, 2017</completion_date>
  <primary_completion_date type="Actual">November 8, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Modifications of functional MRI parameters</measure>
    <time_frame>Before radioembolization and up to 6 months after radioembolization</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between functional MRIs parameters and tumoral response</measure>
    <time_frame>Measured 6 months after radioembolization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of alternative morphological response criteria : EASL (European Association for study of the liver) and mRECIST (m response evaluation criteria in solid tumor) criteria. Link with RECIST response.</measure>
    <time_frame>2 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of VEGF (vascular endothelial growth factor) release</measure>
    <time_frame>From day 0 to 2 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>RMIs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional RMIs</intervention_name>
    <arm_group_label>RMIs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Early, intermediate, advanced, non metastatic Hepatocellular Carcinoma. Indication for
             radioembolization validated after pluridisciplinary committee meeting.

          -  Isolated target on initial imagery (invasive hepatocellular carcinoma excluded)

          -  WHO (World Health organization) Performance status: 0, 1 or 2

          -  If cirrhosis, Child A score with total bilirubin less than 30 micromoles per liter

          -  Creatinine clearance more or equal to 30 mL/min

          -  Patient informed and consent signature obtained

        Exclusion Criteria:

          -  Invasive hepatocellular carcinoma without any isolated tumor

          -  Disease needing 2 injections of Therasphere

          -  Thrombosis extending into the porta(thrombosis of one of left or right branch
             authorized), extra hepatic metastasis

          -  Previous treatment by chemoembolization, radiofrequency less than 3 months before
             radioembolization

          -  No antiangiogenic concomitant treatment, 15 days before and 15 days after
             radioembolization, including Sorafenib

          -  Associated disease which could prevent patient from receiving treatment

          -  RMI contre-indication(particle or metal prosthesis, pacemaker, claustrophobia) or
             contrast product contre-indication (allergy)

          -  Patient already participating in an other therapeutic trial with an experimental drug

          -  Pregnant or childbearing potential women or breastfeeding women

          -  minors, persons deprived of liberty or protected adults (maintenance of justice,
             guardianship or supervision) Unable to comply with trial medical follow-up for
             geographical, social or psychological reasons

          -  Unable to sign an informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien EDELINE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Eugène Marquis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Eugène Marquis</name>
      <address>
        <city>Rennes</city>
        <zip>35042</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2013</study_first_submitted>
  <study_first_submitted_qc>December 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2013</study_first_posted>
  <last_update_submitted>November 20, 2017</last_update_submitted>
  <last_update_submitted_qc>November 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

